LinkedIn Profile

Access Clearside Biomedical historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
nasdaq:clsd 9093014 Aug 11th, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 10th, 2021 10:31PM Aug 10th, 2021 10:31PM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 10th, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 10th, 2021 10:01AM Aug 10th, 2021 10:01AM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 9th, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 9th, 2021 08:37AM Aug 9th, 2021 08:37AM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 8th, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 8th, 2021 05:53PM Aug 8th, 2021 05:53PM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 7th, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 6th, 2021 10:23PM Aug 7th, 2021 04:45PM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 6th, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 6th, 2021 09:05AM Aug 6th, 2021 09:05AM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 5th, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 4th, 2021 11:57PM Aug 5th, 2021 11:58AM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 4th, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 4th, 2021 08:53AM Aug 4th, 2021 08:53AM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 3rd, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 3rd, 2021 08:04AM Aug 3rd, 2021 08:04AM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005
nasdaq:clsd 9093014 Aug 2nd, 2021 12:00AM Clearside Biomedical, Inc. 1.2K 38.00 Open Pharmaceuticals Aug 2nd, 2021 10:06AM Aug 2nd, 2021 10:06AM Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector™ targeting the suprachoroidal space (SCS) offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations such as gene therapy. For more information, please visit www.clearsidebio.com. Open Ophthalmology, Retinal Disease, uveitis, diabetic macular edema, retinal vein occlusion , suprachoroidal, Wet-AMD, gene therapy Open 900 North Point Parkway, Suite 200 Alpharetta GA US 30005

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.